13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001444043
Total reported value
$1.1B
$1.1B
31 檔
161.3%
In Q1 2025, Camber Capital Management LP's U.S. equity holdings reached a combined market value of $1.1B, distributed across 31 disclosed stock positions.
In Q1 2025, Camber Capital Management LP displayed an active expansion posture, initiating 31 new positions and adding to 0 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 29.81% | — | -40.00% | |
| 2 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 9.05% | — | +40.19% | |
| 3 | PFE | Pfizer Inc | Stock-Healthcare | 8.37% | — | -7.00% | |
| 4 | BAX | Baxter International Inc | Stock-Healthcare | 6.99% | — | +24.32% | |
| 5 | HUM | Humana Inc | Stock-Healthcare | 6.81% | — | +11.54% | |
| 6 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 5.76% | — | — | |
| 7 | CVS | Cvs Health CORP | Stock-Healthcare | 5.42% | — | -25.00% | |
| 8 | GMED | Globus Medical Inc - A | Stock-Healthcare | 3.25% | — | +2.04% | |
| 9 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 2.72% | — | -53.13% | |
| 10 | CI | THE Cigna Group | Stock-Healthcare | 2.34% | — | +33.33% | |
| 11 | VTRS | Viatris Inc | Stock-Healthcare | 2.32% | — | -50.00% | |
| 12 | QGEN | Qiagen N.V. | Stock-Healthcare | 2.00% | — | — | |
| 13 | ASND | Ascendis Pharma A/S | Stock-Other | 1.94% | — | -56.25% | |
| 14 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 1.81% | — | -20.00% | |
| 15 | BKD | Brookdale Senior Living Inc | Stock-Other | 1.39% | — | -55.15% | |
| 16 | GSK | Gsk Plc-spon Adr | Stock-Healthcare | 1.38% | — | -86.67% | |
| 17 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 1.26% | — | +11.11% | |
| 18 | CON | Concentra Group Holdings Par | Stock-Other | 1.23% | — | -54.29% | |
| 19 | EVH | Evolent Health Inc - A | Stock-Other | 1.01% | — | -25.00% | |
| 20 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 0.78% | — | +16.00% | |
| 21 | MYGN | Myriad Genetics Inc | Stock-Other | 0.74% | — | -24.19% | |
| 22 | ZIMV | Zimvie Inc | Stock-Other | 0.72% | — | -30.83% | |
| 23 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.61% | — | — | |
| 24 | DNLI | Denali Therapeutics Inc | Stock-Other | 0.60% | — | -44.44% | |
| 25 | ANAB | Anaptysbio Inc | Stock-Other | 0.50% | — | -40.00% | |
| 26 | TBPH | Theravance Biopharma, Inc. | Stock-Other | 0.32% | — | — | |
| 27 | TXG | 10x Genomics Inc-class A | Stock-Other | 0.31% | — | — | |
| 28 | INGN | Inogen Inc | Stock-Other | 0.25% | — | -51.25% | |
| 29 | GPCR | Structure Therapeutics Inc | Stock-Other | 0.18% | — | — | |
| 30 | OSUR | Orasure Technologies Inc | Stock-Other | 0.11% | — | -78.82% | |
| 31 | GMAB | Genmab A/s -sp Adr | Stock-Other | 0.03% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SPY | Ss Spdr S&p 500 ETF Trust-us | — | NEW | New buy |
| 2 | ZBH | Zimmer Biomet Holdings Inc | — | NEW | New buy |
| 3 | PFE | Pfizer Inc | — | NEW | New buy |
| 4 | BAX | Baxter International Inc | — | NEW | New buy |
| 5 | HUM | Humana Inc | — | NEW | New buy |
| 6 | XBI | Ss Spdr S&p Biotech ETF | — | NEW | New buy |
| 7 | CVS | Cvs Health CORP | — | NEW | New buy |
| 8 | GMED | Globus Medical Inc - A | — | NEW | New buy |
| 9 | PTCT | Ptc Therapeutics Inc | — | NEW | New buy |
| 10 | CI | THE Cigna Group | — | NEW | New buy |
| 11 | VTRS | Viatris Inc | — | NEW | New buy |
| 12 | QGEN | Qiagen N.V. | — | NEW | New buy |
| 13 | ASND | Ascendis Pharma A/S | — | NEW | New buy |
| 14 | SRPT | Sarepta Therapeutics Inc | — | NEW | New buy |
| 15 | BKD | Brookdale Senior Living Inc | — | NEW | New buy |
| 16 | GSK | Gsk Plc-spon Adr | — | NEW | New buy |
| 17 | BMRN | Biomarin Pharmaceutical Inc | — | NEW | New buy |
| 18 | CON | Concentra Group Holdings Par | — | NEW | New buy |
| 19 | EVH | Evolent Health Inc - A | — | NEW | New buy |
| 20 | IONS | Ionis Pharmaceuticals Inc | — | NEW | New buy |
| 21 | MYGN | Myriad Genetics Inc | — | NEW | New buy |
| 22 | ZIMV | Zimvie Inc | — | NEW | New buy |
| 23 | MLTX | Moonlake Immunotherapeutics | — | NEW | New buy |
| 24 | DNLI | Denali Therapeutics Inc | — | NEW | New buy |
| 25 | ANAB | Anaptysbio Inc | — | NEW | New buy |
| 26 | TBPH | Theravance Biopharma, Inc. | — | NEW | New buy |
| 27 | TXG | 10x Genomics Inc-class A | — | NEW | New buy |
| 28 | INGN | Inogen Inc | — | NEW | New buy |
| 29 | GPCR | Structure Therapeutics Inc | — | NEW | New buy |
| 30 | OSUR | Orasure Technologies Inc | — | NEW | New buy |
| 31 | GMAB | Genmab A/s -sp Adr | — | NEW | New buy |
According to official SEC Form 13F filings, Camber Capital Management LP reported a total U.S. public equity portfolio value of $1.1B across 31 disclosed positions in Q1 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SPY, ZBH, PFE) accounted for 161.3% of total reported equity market value during Q1 2025.
Top New Position Initiated
SPY
市值: $839.1M
During Q1 2025, Camber Capital Management LP's top holdings by market value included SPY (29.8%)、ZBH (9.1%)、PFE (8.4%). The largest single position, SPY, represented 29.8% of total portfolio value.
In Q1 2025, Camber Capital Management LP made 31 total portfolio adjustments, initiating 31 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.